Search

Boehringer Ingelheim Empowers 380 Regional Experts with Latest Insights in Cardio-Renal-Metabolic Care

Boehringer Ingelheim hosted the ‘CRM 360 standalone meeting’, ‘IMETA CRM Discussions for EXperts (MEDEX)’, to discuss the latest advances in the management of cardio-renal-metabolic conditions

Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts

Boehringer Ingelheim hosted the ‘CRM Summit’ to facilitate exchanges and discussions on the latest advances in the management of cardiovascular, renal, and metabolic diseases to help improve patient outcomes across India, the Middle East and Africa

Metabolic Diseases

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.

Cardiometabolic Research

Read about our patient-centric approach to cardiometabolic disease research.

It’s Your Heart. Protect It. The Podcast.

In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.

Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio

Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio-Metabolism, Respiratory Diseases and Stroke Management

Harold Heart and Friends

The cardiovascular, renal and metabolic systems are interconnected and dysfunction in one system may lead to dysfunction in the other.

How do I treat mild to moderate renal impairment with Pradaxa®

Systemic sclerosis physician video

In this video Professor Chris Denton (Consultant Rheumatologist) discusses his experience diagnosing systemic sclerosis, also known as scleroderma

Europe needs a vibrant research eco-system

At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.

Partnering in Central Nervous System Diseases

We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease

Clinical Trial Demonstrates Positive Top-Line Results Reducing Risk Cardiovascular

Clinical Trial Demonstrates Positive Top-Line Results in Reducing the Risk for Cardiovascular Death or Hospitalisation due to Heart Failure

Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting

Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes

Interconnected CRM conditions

Learn about the interconnectivity between the heart, kidney and metabolic systems

Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together

Central Nervous System Diseases

Find out more about our research and development in central nervous system diseases

Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy

Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk

Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk factors associated with type 2 diabetes

Cairo Tower lights up in Blue for World Diabetes Day

CardioMetabolic_infographic_12SH

Partnering_In_CARDIOMETABOLIC_0

Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia

Boehringer Ingelheim is driving localization capacities with robust partnerships in alignment with Vision 2030

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Search

Boehringer Ingelheim Empowers 380 Regional Experts with Latest Insights in Cardio-Renal-Metabolic Care

Elevating Cardio-Renal-Metabolic Care: Boehringer Ingelheim Imparts Latest Insights to 400 Regional Experts

Metabolic Diseases

Cardiometabolic Diseases

Cardiometabolic Research

It’s Your Heart. Protect It. The Podcast.

Boehringer Ingelheim Saudi Arabia Hosts Virtual Summit on the Latest Updates in Diabetes, Cardio

Harold Heart and Friends

How do I treat mild to moderate renal impairment with Pradaxa®

Systemic sclerosis physician video

Europe needs a vibrant research eco-system

Partnering in Central Nervous System Diseases

Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease

Clinical Trial Demonstrates Positive Top-Line Results Reducing Risk Cardiovascular

Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting

Interconnected CRM conditions

Boehringer Ingelheim Brings Hundreds of Leading Cardiologists from Eight Countries Together

Central Nervous System Diseases

Empagliflozin Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy

Local healthcare community raise alarm bells on growing trend of cardiovascular disease risk

Cairo Tower lights up in Blue for World Diabetes Day

CardioMetabolic_infographic_12SH

CardioMetabolic_infographic_12SH

Partnering_In_CARDIOMETABOLIC_0

Boehringer Ingelheim and Alpha Pharma Collaborate to localize the production of one of its Type 2 Diabetes Medicines in Saudi Arabia